KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Assets Average: 2010-2025

Historic Assets Average for Emergent BioSolutions (EBS) over the last 13 years, with Sep 2025 value amounting to $1.4 billion.

  • Emergent BioSolutions' Assets Average fell 3.78% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 3.78%. This contributed to the annual value of $1.6 billion for FY2024, which is 35.61% down from last year.
  • Emergent BioSolutions' Assets Average amounted to $1.4 billion in Q3 2025, which was up 1.23% from $1.4 billion recorded in Q2 2025.
  • Emergent BioSolutions' Assets Average's 5-year high stood at $3.1 billion during Q1 2023, with a 5-year trough of $1.4 billion in Q1 2025.
  • Moreover, its 3-year median value for Assets Average was $1.7 billion (2024), whereas its average is $1.8 billion.
  • Its Assets Average has fluctuated over the past 5 years, first rose by 25.56% in 2021, then tumbled by 40.70% in 2024.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Assets Average stood at $2.9 billion in 2021, then grew by 4.07% to $3.0 billion in 2022, then slumped by 38.70% to $1.9 billion in 2023, then fell by 22.84% to $1.4 billion in 2024, then dropped by 3.78% to $1.4 billion in 2025.
  • Its Assets Average stands at $1.4 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.4 billion for Q1 2025.